Surrozen Provides Third Quarter 2023 Financial Results
Expect to announce data from SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers in Q1 2024
Expect to announce data from SZN-1326 Phase 1a clinical trial in healthy volunteers in Q1 2024
Related news for (SRZN)
- Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway
- Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update
- Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates
- Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases
- surrozen earns $10 million milestone payment in retinal diseases collaboration